Hand eruption after intravenous administration of bevacizumab
First published: 04 January 2011
No abstract is available for this article.
References
- 1
Shord SS,
Bressler LR,
Lauryn A,
Tierney LA,
Sandra Cuella S,
George A.
Understanding and managing the possible adverse effects associated with bevacizumab.
Am J Health Syst Pharm
2009; 66: 999–1013.
- 2
Saif MW,
Longo WL,
Israel G.
Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
Clin Colorectal Cancer
2008; 7: 144–148.
- 3
Gotlib V,
Khaled S,
Lapko I,
Mar N,
Saif MW.
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
Anticancer Drugs
2006; 17: 1227–1229.
- 4
Robert C.
Effets secondaires cutanés des molecules anti-angiogéniques.
Bull Cancer
2007; 94: S260–S264.
- 5
Motl S.
Bevacizumab in combination chemotherapy for colorectal and other cancers.
Am J Health Syst Pharm
2005; 62: 1241.
- 6
Amselem L,
Diaz-Llopis M,
Garcia-Delpech S,
Montero J,
Palomares P,
Cervera E.
Papulopustular eruption after intravitreal bevazicumab.
Acta Ophthalmol
2009; 87: 110–111.
- 7
Shima C,
Sakaguchi H,
Gomi F
et al.
Complications in patients after intravitreal injection of bevacizumab.
Acta Ophthalmol
2008; 86: 372–376.
- 8
Vano-Galvan S,
Moreno C,
Medina J,
Pérez-García B,
García-López JL,
Jaén J.
Perforating dermatosis in a patient receiving bevacizumab.
J Eur Acad Dermatol Venereol
2009; 23: 972–974.
- 9
Rodemer Y,
Bernardo-Noriega F.
Use of Allopurinol for the treatment of palmar-plantar erythrodysesthesia. World International Property Organization (WO/2007/138103), December 2007.
- 10
Porta C,
Moroni M,
Nastasi G.
Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis.
Am J Clin Oncol
1994; 17: 246–247.
